MANAGEMENT
OF EG/EoD

THERE ARE CURRENTLY NO FDA-APPROVED TREATMENTS FOR EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS (EG/EoD), and patients need effective therapies with manageable side effects that target the underlying cause1,2

  • Current treatment regimens used to manage symptoms are limited to3:
    • Dietary modification
    • Proton pump inhibitors
    • Swallowed topical steroids
    • Systemic steroids
  • Existing therapies have not been assessed for safety and efficacy in controlled clinical trials for EG/EoD and/or may be inappropriate for chronic use4

Therapies that target the underlying cause of EG/EoD – eosinophils and mast cells – are urgently needed1,2

EDUCATION AND RESOURCES ARE AVAILABLE FOR EG/EoD

References:  1. Pesek RD, Reed CC, Muir AB, et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis and colitis based on 10 year data across a multi-center consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228.  2. Youngblood BA, Brock EC, Leung J, et al. Monoclonal antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. 2019;4(19):e126219. doi:10.1172/jci.insight.126219.  3. Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol. 2019;57(2):272-285. doi:10.1007/s12016-019-08732-1.  4. Egan M, Furuta GT. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;121(2):162-167. doi:10.1016/j.anai.2018.06.013.